On the afternoon of November 6, Apeloa’s Shanghai CDMO R&D Center hosted a brief award ceremony. Two senior executives from an international innovative biotech company traveled from the United States to present a trophy to the Apeloa project team and recognize Apeloa as a “deeply trusted R&D and manufacturing partner.”
Behind this recognition lies the trust built through one successful batch delivery after another since 2024. The project presented significant process challenges. The previous overseas supplier had multiple issues with lead times and manufacturing consistency, severely disrupting the client’s overall CMC supply chain, compromising the stable and timely supply of clinical trial materials, and affecting the overall progression of the pipeline. After the project was transferred to Apeloa, the process team systematically identified and optimized scale-up risks in the original process. Leveraging its mature scale-up manufacturing platform and robust quality management system, Apeloa made the contributions to keep the project on track against the overall timeline. Multiple production batches were completed and delivered on schedule, with both quality and quantity assured, supporting the steady progression of the drug candidate through PPQ and providing a reliable supply guarantee for its subsequent NDA submission.
This recognition is another international acknowledgment Apeloa has received in 2026. Earlier this year, the company received the 2026 Frost & Sullivan Global CDMO Company of the Year Award in August and the 2026 “Service Excellence Award” from a leading global pharmaceutical company in October. This latest recognition from an international innovative biotech company further demonstrates Apeloa’s ability to serve both large multinational pharmaceutical companies and innovative biotech companies.
As a leading CDMO in China, Apeloa has developed a clear strength in undertaking highly complex projects. In recent years, the company has provided global clients with integrated one-stop services covering process development, scale-up, commercial manufacturing, and regulatory support. It has continuously strengthened its ability to manage risks in complex projects and can take on high-difficulty, high-priority new drug development programs. While maintaining strict IP confidentiality, Apeloa flexibly aligns with clients’ project timelines and regulatory requirements, supporting global innovative drug substance R&D and manufacturing.
Recognition is both an affirmation and the starting point for the next collaboration. Going forward, Apeloa will continue to strengthen its technical and supply chain capabilities, optimize project management and collaboration models, and provide stable, reliable, and high-quality CDMO solutions to innovative drug partners worldwide.
